---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-025891"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:19:52.639742+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cerus Q4 net loss narrows to $1.3M; achieves adj. EBITDA breakeven; reiterates FY2024 guidance

## Summary
- Q4 net loss attributable to Cerus narrowed to $1.3M ($0.01/share) from $13.6M ($0.08) a year ago.
- Q4 total revenue $53.3M (+4% YoY); product revenue $46.8M (+6% YoY), driven by North America platelet growth.
- Achieved Q4 adjusted EBITDA breakeven at +$4.7M vs -$3.7M in Q4 2022.
- Reiterated FY2024 product revenue guidance of $172-175M; INTERCEPT Fibrinogen Complex expected $8-10M.
- Cash and investments $65.9M at Dec 31; net cash used in ops $43.2M for FY2023, up from $25.6M.

## SEC filing metadata
- accession: 0000950170-24-025891
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/cers-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-025891
- JSON: https://secwatch.observer/filing/0000950170-24-025891.json
- Plain text: https://secwatch.observer/filing/0000950170-24-025891.txt

## Key facts
- Earnings Releases
  CERUS CORP reported Fourth Quarter 2023 results: revenue $53,342, net income Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, EPS $0.01 per basic and diluted share.
  - Period: Fourth Quarter 2023
  - Revenue: $53,342
  - Net income: Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million
  - EPS: $0.01 per basic and diluted share
  - Result: reported results
  source text: Total Revenue $53,342 $51,321 $2,021 4% $186,797 $188,315 $(1,518) -1%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm
- Earnings Releases
  CERUS CORP reported Full-Year 2024 results: revenue $172-175 Million. Guidance reaffirmed.
  - Period: Full-Year 2024
  - Revenue: $172-175 Million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm
- Earnings Releases
  CERUS CORP reported Fourth Quarter and Full-Year 2023 results: revenue $53,342, net income Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million, EPS $0.01 per basic and diluted share. Guidance reaffirmed.
  - Period: Fourth Quarter and Full-Year 2023
  - Revenue: $53,342
  - Net income: Net loss attributable to Cerus Corporation for the fourth quarter of 2023 was $1.3 million
  - EPS: $0.01 per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: % 2023 2022 $ % Product Revenue $46,768 $44,034 $2,734 6% $156,367 $162,048 $(5,681) -4% Government Contract Revenue 6,574 7,287 (713) -10% 30,430 26,267 4,163 16% Total Revenue $53,342 $51,321 $2,021 4% $186,797 $188,315 $(1,518) -1% • The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.